<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00206232</url>
  </required_header>
  <id_info>
    <org_study_id>H - 13988</org_study_id>
    <nct_id>NCT00206232</nct_id>
  </id_info>
  <brief_title>Novel Treatment for Diastolic Heart Failure in Women</brief_title>
  <official_title>Novel Treatment for Diastolic Heart Failure in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to collect information about the potential benefit and safety of&#xD;
      low dose spironolactone for a patient with diastolic heart failure (DHF) and to determine&#xD;
      whether spironolactone can cause the patient's condition to improve.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with diastolic heart failure defined based on clinical symptoms, echocardiography&#xD;
      diastology parameters and brain natriuretic peptide level will be randomized in a 1:1 fashion&#xD;
      to either placebo or spironolactone 25mg daily for 6 months. They will be assessed over this&#xD;
      6 month period for improvement in exercise capacity, clinical symptoms, echocardiography&#xD;
      diastology parameters, and biomarkers specific for heart failure. Safety of spironolactone in&#xD;
      this patient population will also be assessed by recording adverse events and following&#xD;
      electrolytes, blood urea nitrogen, and creatinine levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Six minute walk distance</measure>
    <time_frame>Baseline, then 3 and 6 months after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiography parameters of diastolic function</measure>
    <time_frame>Baseline, then 3 and 6 months after randomization</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Procollagen peptides, troponin I, tumor necrosis factor alpha, Brain Natriuretic Peptide</measure>
    <time_frame>Baseline then 3 and 6 months after randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Electrolytes, blood urea nitrogen, creatinine</measure>
    <time_frame>Screening and enrollment then 10 days, 4 weeks, 11 weeks, 13 weeks, and 15 weeks after randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life Questionaire</measure>
    <time_frame>Baseline, then 3 and 6 months after randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>New York Heart Association Classification</measure>
    <time_frame>Baseline then 3 and 6 months after randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From randomization until trial completion at 6 months.</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>Research subjects are randomized to placebo versus spironolactone 25mg daily and followed for 6 months.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Spironolactone</arm_group_label>
    <other_name>Aldactone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women who are 18 years of age or older.&#xD;
&#xD;
          -  Women with clinical heart failure for &gt; 2 months.&#xD;
&#xD;
          -  Women with left ventricular ejection fraction &gt; 50% within 2 months of screening.&#xD;
&#xD;
          -  Women with New York Heart Association class II or III heart failure symptoms.&#xD;
&#xD;
          -  Brain Natriuretic Peptide &gt; 62 pg/ml within 2 months of screening.&#xD;
&#xD;
          -  Patient on angiotensin converting enzyme inhibitor or angiotensin receptor blocker&#xD;
             therapy for at least 1 month.&#xD;
&#xD;
          -  Blood Pressure no more than 150/95.&#xD;
&#xD;
          -  Patient able to walk more than 50 meters at the time of enrollment.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current treatment with spironolactone.&#xD;
&#xD;
          -  Severe hepatic impairment.&#xD;
&#xD;
          -  Creatinine &gt; 2.5 mg/dl&#xD;
&#xD;
          -  Potassium &gt; 5.0 mEq/L&#xD;
&#xD;
          -  Intolerance to spironolactone in the past.&#xD;
&#xD;
          -  Significant valvular heart disease, pericardial disease, or severe chronic lung&#xD;
             disease with cor pulmonale.&#xD;
&#xD;
          -  Unstable angina or myocardial infarction within the past 4 weeks.&#xD;
&#xD;
          -  Severe peripheral vascular disease or other physical conditions that would limit the&#xD;
             walking distance.&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Participation in any other drug trial within 30 days prior to randomization.&#xD;
&#xD;
          -  Inability to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karla M Kurrelmeyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor College of Medicine Heart Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>February 15, 2013</last_update_submitted>
  <last_update_submitted_qc>February 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Karla Kurrelmeyer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Diastolic Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 4, 2021</submitted>
    <returned>January 21, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

